degradation of hyaluronate by synovia from patients with rheumand redistribution in rejecting rat kidney graft. Relationship to the transplantation edema. 
Primary hyperoxalurias Toxicity

PH1
Oxalate is a useless end-product of metabolism and is normally completely excreted by the kidneys (normal PH1-a 'nephrological liver disease'-is due to a defect excretion <0.5 mmol (45 mg)/24 h/1.73 m2). Oxalate or absence of liver-specific peroxisomal alanine:glyoxand calcium oxalate (CaOx) crystals, once believed to ylate aminotransferase (AGT ), resulting in elevated be biologically inert, exert toxic effects on renal epithe-urinary excretion of oxalate and (in most cases) of lial cells [1 (A 11,12); 2-4]. These effects are compar-glycolate. The AGXT gene is located on chromosome able to those resulting from oxidative stress on tissues, 2q37.3 and spans over 11 exons [9] . Over 25 different because oxalate increases the production of free rad-mutations have been found so far. Around 30% of icals [2] . The extremely high urinary oxalate concentra-patients have the G 630 A mutation, leading to a Gly 170 A tions in patients with PH may therefore be harmful. amino acid substitution, which is mostly associated Thus, any increase in oxalate not only has a strong with a C 154 T polymorphism (Pro 11 Leu). This mutation effect on the urinary saturation of CaOx (10 times as is particularly interesting because it leads to an unparmuch as an equimolar increase of calcium), but in alleled protein trafficking defect in which AGT is addition may lead to direct tubular damage.
mistargeted from peroxisomes to mitochondria. Further studies have yielded insights into some of the fundamental differences in the way proteins are tar-
Intestinal absorption
geted to, and imported into, peroxisomes and mitochondria [9]. Only 5-10% of the urinary oxalate normally originates Clinically, PH1 is also very heterogeneous, with the from daily nutrition. This fraction is even lower in PH spectrum ranging from early ESRF (infantile oxalosis) patients, considering their extremely high endogenous to occasional kidney stones in adults [1] . The clinical oxalate production. However, intestinal absorption heterogeneity is not sufficiently explained, neither by might become a relevant factor if it is increased (as is AGT activity or localization, nor by disease specific the case in some forms of secondary hyperoxaluria). genotypes. Even siblings with an identical mutation may Absence of the anaerobic intestinal oxalate-degrading have a completely different course of the disease [10]. bacterium Oxalobacter formigenes (which is found in Diagnosis of PH1 is still being missed or delayed all up to 80% of the normal population) has been shown too often, and figures reported represent a minimum. to be associated with (secondary) hyperoxaluria in Data from the UK, Switzerland and France suggest patients with cystic fibrosis and in patients with recur-that 1 in 60 000 to 120 000 children suffers from PH1 rent urolithiasis [1 (A 16); 5]. Another cause of [1 (A 2); 11]. The disease is far more common in increased intestinal oxalate absorption is calcium certain countries like Tunisia, where PH1 is the cause restriction, as less calcium is available to bind oxalate of ESRF in 13% of paediatric patients as compared to and to form (insoluble) CaOx complexes in the gut. Plasma oxalate (P Ox ) and plasma CaOx saturation Therapy of PH1 ( b CaOx ) are increased early in PH patients [6, 7] . Therefore the main purpose of therapy is to lower P Ox Generous fluid intake and administration of potassium and b CaOx (to which P Ox is significantly correlated) or citrate or phosphate together with pyridoxine (vitamin at least to prevent its steady increase. Both parameters B 6
) is still the basis of therapy. Attempts to reduce the are inversely correlated with GFR, hence the risk of glyoxalate or glycolate pool have not yet been successsystemic CaOx deposition (oxalosis) is increased in ful [1 (A 14) ]. There was agreement to define pyridoxrenal insufficiency, even before end-stage renal failure ine responsiveness as >30% reduction of urinary ( ESRF ) occurs [6 ] .
oxalate excretion from baseline after stepwise increase of daily dosage of pyridoxine (5-10-15-20 mg/kg after several weeks) [1 (A 15)].
Liver biopsy
Transplantation Urinary metabolites often are not conclusive for diagnosis of PH1 or PH2. The enzyme defects of PH1 According to the latest European Oxalosis Registry Report, actuarial patient survival (98 grafts in 93 and PH2 can now be determined in hepatic tissue from patients) is 80% at 6 years for combined liver/kidney etc.). The search for the metabolic defect(s) in atypical PH, the term preferred at the Workshop, is ongoing. transplantation (with a much poorer outcome for patients <5 years of age) [1 (A 19) ]. This treatment modality is at present the method of choice for PH1 Conclusion patients in ESRF. Isolated kidney transplantation, advocated in the USA [1 (A 21)], may still be an In conclusion, much progress has been made during alternative, e.g. in B 6 -responsive patients [7] . No such recent years, and molecular genetics and enzyme diatherapy is available in some developing countries gnostics have firmly been established in PH1 and PH2. having a high incidence of PH1. Dialysis is no alternat-However, considerable effort is necessary to explain ive except for a very limited time.
the discrepancy between genotype and phenotype in Why not perform pre-emptive (isolated) liver trans-PH1 and to define the underlying metabolic defects of plantation [1 (A 22, 11)]? Thus far, some 10 patients atypical PH. The optimal treatment, especially for with PH1 not in renal failure have been treated this patients with PH1 and renal insufficiency remains a way with reasonable results. However, some of the matter of debate, and not all agree with early enzyme patients might have maintained their renal function replacement therapy=pre-emptive liver transplantawithout intervention. It is impossible to establish guide-tion. Intensified research in PH will also benefit the lines, and it seems unlikely that pre-emptive liver large number of patients with secondary hyperoxalurtransplantation will become popular in PH1.
ias. No doubt, the 6th PH workshop will be exciting again!
Prospects of gene therapy
Considerable problems need to be overcome. In ana-References logy to auxiliary liver transplantation (which does not
